Eli Lilly (LLY)

Today, May 28, 2026, investors piled into Snowflake after its Amazon pact and earnings beat, even as the Dow barely budged.

What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.4% in the afternoon session after CVS restored Zepbound as a co-preferre...

Novo Nordisk lost its lead in the GLP-1 race, but Eli Lilly's valuation is a bit rich.

Eli Lilly (NYSE:LLY) shares jumped on Thursday morning after securing expanded PBM coverage for its blockbuster obesity treatments, Zepbound and Foundayo.

Hims & Hers is acquiring Australian telehealth platform Eucalyptus as part of its international expansion plan while using $350 million in convertible senior notes.

Expense ratios, yield, and sector breadth set these healthcare ETFs apart—see how their risk profiles and portfolio strategies compare.

Eli Lilly has outpaced the Nasdaq Composite over the past year, and analysts remain very confident in its longer-term trajectory.

Johnson & Johnson has outperformed the Dow Jones over the past year, and analysts remain moderately optimistic about the stock’s outlook.

Buying and holding stocks is an excellent strategy to increase your wealth.

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recentl...

Megacap stocks dominate their sectors and their actions influence economies worldwide. The flip side though is that their sheer size means they have less roo...

There is no reason to panic just yet.

Eli Lilly's fundamentals matter more than Trump's stock purchases.

Eli Lilly shares inch higher as the company announced three acquisitions for nearly $4 billion. Here’s why each of the three vaccine makers it’s buying is bullish for LLY stock.

A closer look at portfolio makeup, yield, and risk reveals what sets these two iShares healthcare funds apart for investors seeking sector exposure.

A concentrated pharma focus sets VanEck apart from iShares’ broader healthcare approach. See how portfolio differences shape risk and income profiles.

Surging demand for the memory chipmaker's AI products has sent its stock soaring. But a rally this steep doesn't come without risk.

Consumer demand for Eli Lilly's weight-loss treatments continues to rise.

This biotech focuses on biologic therapies for immunological diseases, with lead candidates in nephrology and infectious disease.

Eli Lilly acquires Curevo, LimmaTech, and Vaccine Co. to expand its infectious disease portfolio and advance long-term disease prevention.

For some types of restaurants, the damage is bigger.

Eli Lilly acquired three infectious diseases companies for up to $3.83 billion. Lilly stock ticked higher in response.

Walmart's recent run of outperformance could be coming to an end.

These players are seeing exciting results in clinical trials.

Chamath Palihapitiya reacted on X after Eli Lilly's VERVE-102 showed strong Phase 1b LDL cholesterol reduction results.